(Total Views: 346)
Posted On: 09/21/2018 5:39:37 PM
Post# of 72451
I think scgmck1's post got spell checked from Menon to mean. This is the statement from the 8k:
As previously disclosed, Innovation Pharmaceuticals Inc. (the “Company”) approved steps in early 2018 to focus its efforts on clinical trials for its lead drug candidates. Among other changes, the salary of Dr. Krishna Menon, the Company’s President of Research, was reduced by 50%, reflecting a decrease in research unrelated to clinical trials. On September 18, 2018, the Company notified Dr. Menon of the termination of his continued employment with the Company in order for the Company to further focus its resources on clinical trials for its lead drug candidates. Dr. Menon will continue to serve on the Company’s Board of Directors.
As previously disclosed, Innovation Pharmaceuticals Inc. (the “Company”) approved steps in early 2018 to focus its efforts on clinical trials for its lead drug candidates. Among other changes, the salary of Dr. Krishna Menon, the Company’s President of Research, was reduced by 50%, reflecting a decrease in research unrelated to clinical trials. On September 18, 2018, the Company notified Dr. Menon of the termination of his continued employment with the Company in order for the Company to further focus its resources on clinical trials for its lead drug candidates. Dr. Menon will continue to serve on the Company’s Board of Directors.
(2)
(0)
